Development of individualized treatment for congenital ovarian dysplasia syndrome
10.3760/cma.j.issn.2095-428X.2019.20.018
- VernacularTitle: 先天性卵巢发育不良综合征的个体化治疗进展
- Author:
Xinzhu ZHANG
1
;
Zhixin ZHANG
2
Author Information
1. Institute of Clinical Medical Science, Beijing University of Chinese Medicine, Beijing 100029, China
2. Department of International, China-Japan Friendship Hospital, Beijing 100029, China
- Publication Type:Review
- Keywords:
Congenital ovarian dysplasia;
Individualized treatment;
Recombinant human growth hormone;
Pharmacogenomics
- From:
Chinese Journal of Applied Clinical Pediatrics
2019;34(20):1591-1594
- CountryChina
- Language:Chinese
-
Abstract:
Congenital ovarian dysplasia syndrome is a feminine genetic disease which is rarely seen.Its clinical manifestations include short stature and primary ovarian insufficiency, in addition of which could cause multi-systema-tic complications.According to its therapeutic methods, recombinant human growth hormone and Estrogen are normally used to improve stature and the development of gonad.However, these methods are long-lasting and with great expense, which may result in economic and emotional burdens on patients and their family.On the contrary, individual therapies has a rather precise pharmacogenetical evaluation on patients and their disease, which could effectively decrease iatrogenic loss while enhancing the curative effect.
